[1] Chan, E.; Tan, M.; Xin, J.; Sudarsanam, S.; Johnson, D.E. Interactions between traditional Chinese medicines and Western. Curr. Opin. Drug Discov. Dev. 2010, 13, 50-65.
[2] Yin, Q.W.; Wang, P.; Zhang, A.H.; Sun, H.; Wu, X.H.; Wang, X.J. Ultra-performance LC-ESI/quadrupole-TOF MS for rapid analysis of chemical constituents of Shaoyao-Gancao decoction. J. Sep. Sci. 2013, 36, 1238-1246.
[3] Bai, Q. The influence of Huangqi Guizhi Wuwu Decoction on diabetic peripheral neuropathy and nerve conduction velocity. Chin. Tradit. Pat. Med. 2015, 37, 962-964.
[4] Pang, B.; Zhao, T.Y.; Zhao, L.H.; Wan, F.; Ye, R.; Zhou, Q.; Tian, F.; Tong, X.L. Huangqi Guizhi Wuwu Decoction for treating diabetic peripheral neuropathy: a meta-analysis of 16 randomized controlled trials. Neural Regeneration Res. 2016, 11, 1347-1358.
[5] Hua, W.J.; Bu, P. 68 cases by combination of Chinese and western therapies on diabetic peripheral neuropathy. Jiangsu J. Tradit. Chin. Med. 2008, 40, 65-66.
[6] Wang, B.D.; Shen, X.H. Clinical observation on the treatment of diabetic peripheral neuropathy with modified Huangqi Guizhi Wuwu Decoction. Guide China Med. 2012, 10, 262-264.
[7] Tesfaye, S.; Selvarajah, D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab. Res. Rev. 2012, 28, 8-14.
[8] Gao, C.; Song, J.S.; Xue, X.H.; Xiong, J.; Shang, T.G. Effect comparison of huangqi guizhi wuwu decoction and western medicine for treating diabetic peripheral neuropathy: a systematic review. Liaoning J. Tradit. Chin. Med. 2012, 6, 993-1000.
[9] Zhao, X.L.; Zhang, X.Z.; Di, L.Q.; Wang, S.C.; Cai, B.C.; Du, Q.; Shan, J.J.; Bi, X.L.; Wei, H.M. Exploration of Thoughts and Methods in Study on Material Base of Traditional Chinese Medicinal Herbs Prescriptions. World Sci. Technol. 2009, 11, 488-492.
[10] Lai, K.M.; Cheng, Y.Y.; Tsai, T.H. Integrated LC-MS/MS Analytical Systems and Physical Inspection for the Analysis of a Botanical Herbal Preparation. Molecules. 2015, 20, 10641-10656.
[11] Wang, Y.; Xu, C.; Wang, P.; Lin, X.; Yang, Y.; Li, D.; Li, H.; Wu, X.; Liu, H. Pharmacokinetic comparisons of different combinations of Shaoyao-Gancao Decoction in rats: simultaneous determination of ten active constituents by HPLC-MS/MS. J. Chromatogr. B Anal. Technol. Biomed. life Sci. 2013, 932, 76-87.
[12] Wu, Y.P.; Meng, X.S.; Bao, Y.R.; Wang, S. Pharmacokinetic study of four flavones of Glycyrrhiza in rat plasma using HPLC-MS. J. Ethnopharmacol. 2013, 148, 266-270.
[13] Zhang, Z.; Jia, P.; Zhang, X.; Zhang, Q.; Yang, H.; Shi, H.; Zhang, L. LC-MS/MS determination and pharmacokinetic study of seven flavonoids in rat plasma after oral administration of Cirsium japonicum DC. Extract. J. Ethnopharmacol. 2014, 158, 66-75.
[14] Shao, Y.P.; Zhang, W.; Tong, L.; Huang, J.Y.; Li, D.X.; Nie, W.; Zhu, Y.; Li, Y.F.; Lu, T. Simultaneous determination of eight bioactive components of Qishen Yiqi Dripping Pills in rat plasma using UFLC-MS/MS and its application to a pharmacokinetic study. Biomed. Chromatogr. 2017, 31, 1-13.
[15] Wang, C.H.; Wu, C.S.; Zhang, J.L.; Jin, Y. Systematic considerations for a multicomponent pharmacokinetic study of Epimedii wushanensis herba: From method establishment to pharmacokinetic marker selection. Phytomedicine. 2015, 22, 487-497.
[16] Zhang, Y.F.; Shi, P.Y.; Yao, H.; Shao, Q.; Fan, X.H. Metabolite Profiling and Pharmacokinetics of Herbal Compounds Following Oral Administration of a Cardiovascular Multi-herb Medicine (Qishen Yiqi Pills) in Rat. Curr. Drug Metab. 2012, 13, 510-523.
[17] Lu, T.; Yang, J.; Gao, X.; Chen, P.; Du, F.; Sun, Y.; Wang, F.; Xu, F.; Shang, H.; Huang, Y.; Wang, Y.; Wan, R.; Liu, C.; Zhang, B.; Li, C. Plasma and urinary tanshinol from Salvia miltiorrhiza (Danshen) can be used as pharmacokinetic markers for cardiotonic pills, a cardiovascular herbal medicine. Drug Metab. Dispos. 2008, 36, 1578-1586.
[18] Qi, L.W.; Li, P.; Ren, M.T.; Yu, Q.T.; Wen, X.D.; Wang, Y.X. Application of high-performance liquid chromatography-electrospray ionization time-of-flight mass spectrometry for analysis and quality control of Radix Astragali and its preparations. J. Chromatogr. A. 2009, 1216, 2087-2097.
[19] Chan, W.S.; Durairajan, S.S.K.; Lu, J.H.; Wang, Y.; Xie, L.X.; Kum, W.F.; Koo, I.; Yung, K.K.L.; Li, M. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture. Neurochem. Int. 2009, 55, 414-422.
[20] Rios, J.L.; Waterman, P.G. A review of the pharmacology and toxicology of Astragalus. Phytother. Res. 1997, 11, 411-418.
[21] Ko, J.K.; Lam, F.Y.; Cheung, A.P. Amelioration of experimental colitis by Astragalus membranaceus through anti-oxidation and inhibition of adhesion molecule synthesis. World J. Gastroenterol. 2005, 11, 5787-5794.
[22] Meletis, C.D.; Zabriskie, N. Nutritional and botanical approaches to antiaging. Altern. Complement. Ther. 2006, 12, 269-274.
[23] Garcia de Yebenes, J.; Yebenes, J.; Mena, M.A. Neurotrophic factors in neurodegenerative disorders: model of Parkinson’s disease. Neurotox. Res. 2000, 2, 115-137.
[24] Wang, L.; Zhang, Z.; Yu, X.Y.; Zhao, H.Y.; Wu, X.Y.; Chen, X.; Zhou, X.H.; Li, L. An efficient, sensitive and accurate method for the detection of astragaloside IV in Chinese functional spirit by ultra-performance liquid chromatography-quadrupole-orbitrap mass spectrometry. Anal. Methods. 2015, 7, 10199.
[25] Liu, S.; Zhang, J. Cardiovascular protective effects of astragaloside IV. J. Chin. Pharm. Sci. 2013, 22, 222-225
[26] Liu, D.Z.; Xie, K.Q.; Ji, X.Q.; Ye, Y.; Jiang, C.L.; Zhu, X.Z. Neuroprotective effect of paeoniflorin on cerebral ischemic rat by activating adenosine A1 receptor in a manner different from its classical agonists. Br. J. Pharmacol. 2005, 146, 604-611.
[27] Wu, Y.M.; Jin, R.; Yang, L.; Zhang, J.; Yang, Q.; Guo, Y.Y.; Li, X.B.; Liu, S.B.; Luo, X.X.; Zhao, M.G. Phosphatidylinositol 3 kinase/protein kinase B is responsible for the protection of paeoniflorin upon H2O2-induced neural progenitor cell injury. Neuroscience. 2013, 240, 54-62.
[28] Chen, T.; Guo, Z.P.; Jiao, X.Y.; Jia, R.Z.; Zhang, Y.H.; Li, J.Y.; Huang, X.L.; Liu, H.J. Peoniflorin suppresses tumor necrosis factor-α induced chemokine production in human dermal microvascular endothelial cells by blocking nuclear factor-κB and ERK pathway. Arch. Dermatol. Res. 2011, 303, 351-360.
[29] Jin, L.; Zhang, L.M.; Xie, K.Q.; Ye, Y.; Feng, L. Paeoniflorin suppresses the expression of intercellular adhesion molecule-1 (ICAM-1) in endotoxin-treated human monocytic cells. Br. J. Pharmacol. 2011, 164, 694-703.
[30] Choi, E.M.; Suh, K.S.; Rhee, S.Y.; Kim, Y.S. Inhibitory effect of paeoniflorin on 368 X methylglyoxal-mediated oxidative stress in osteoblastic MC3T3-E1 cells. Phytomedicine. 2014, 21, 1170-1177.
[31] Choi, J.; Chandrasekaran, K.; Inoue, T.; Muragundla, A.; Russell, J.W. PGC-1α regulation of mitochondrial degeneration in experimental diabetic neuropathy. Neurobiol. Dis. 2014, 64, 118-130.
[32] Dong, H.; Li, R.; Yu, C.; Xu, T.; Zhang, X.; Dong, M. Paeoniflorin inhibition of 6-hydroxydopamine-induced apoptosis in PC12 cells via suppressing reactive oxygen species-mediated PKCδ/NF-κB pathway. Neuroscience. 2015, 287, 70-80.
[33] Li, J.Z.; Yu, S.Y.; Wu, J.H.; Shao, Q.R.; Dong, X.M. Paeoniflorin protects myocardial cell from doxorubicin-induced apoptosis through inhibition of NADPH oxidase. Cancer J. Physiol. Pharmacol. 2012, 90, 1569-1575.
[34] Yang, X.W.; Yao, W.J.; Shi, H.T.; Liu, H.L.; Li, Y.F.; Gao, Y.B.; Liu, R.H.; Xu, L.P. Paeoniflorin protects Schwann cells against high glucose induced oxidative injury by activating Nrf2/ARE pathway and inhibiting apoptosis. J. Ethnopharmacol. 2016, 185, 361-369.
[35] Gao, F.Y.; Hu, Y.S.; Gao, F.; Yang, G.; Xu, Z.H.; Dou, L.L.; Chen, Z.; Fan, C.R. Recent developments in the field of the determination of constituents of TCMs in body fluids of animals and human. J. Pharm. Biomed. Anal. 2014, 87, 241-260. |